Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 280Magnetic Resonance Spectroscopy 233pembrolizumab 220Carboplatin 180Cisplatin 146Biopsy 146Cyclophosphamide 138Paclitaxel 128Nivolumab 118Bevacizumab 106Gemcitabine 105Radiotherapy 90Dexamethasone 83Pemetrexed 79fludarabine 74Docetaxel 74atezolizumab 73Fluorouracil 73Doxorubicin 73Radiation 72Leucovorin 68Rituximab 66Oxaliplatin 64venetoclax 60Prednisone 60durvalumab 58Cetuximab 56Vincristine 55Etoposide 54Lenalidomide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Serotonin 5-HT3 Receptor Antagonists × 30 days × Clear all
NCT06925737 2026-05-29

MK-2400-001

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,440 enrolled
Genitourinary

Prostatic Neoplasms

NCT06780085 2026-05-26

MK-3475-01H

Merck Sharp & Dohme LLC

Phase 2 Recruiting
96 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡